Photo Gallery



News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • MAY 2021 Issue has been successfully launched on 1 May 2021.



B.Rasmitha Reddy*, B.Venkateswara Reddy, K.Navaneetha


Dasatinib is a selective Tyrosine Kinase Inhibitor (TKI) used in treatment of chronic myeloid leukemia (CML) and acute myeloid leukemia (AML). Dasatinib have become first line drug in the pharmacotherapy of patients with CML. This is because the drug possesses tolerability and safety advantages over the other Tyrosine Kinase Inhibitors. Tablets of Dasatinib were prepared using different superdisintegrants (Sodium Starch Glycolate, Crosscarmellose, and Crospovidone) by wet granulation method.Nine formulations (F1-F9) of immediate release oral tablets were prepared by using different disintegrants to get desired release profile.The drug-excipients interaction was investigated by FTIR. The granules and tablets of Dasatinib evaluated for various pre and post compression parameters like Angle of repose Compressibility index, Hausner’s ratio, Tablet hardness, Friability, Weight variation, Drug content and in vitro dissolution. Their results were found satisfactory. DSC studies have shown that drug is stable in the formulation. It is concluded that in vitro dissolution studies show the release is in the following order of superdisintegrants: Crosscarmellose > Sodium Starch Glycolate > Crospovidone. Maximum in vitro dissolution was found to be with Formulation F-2 and it clearly shows due to Crosscarmellose (7.9%).

Keywords: Dasatinib, Crosspovidone,Crosscarmellose sodium,Sodium starch glycolate.

[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More